scholarly journals Prognostic Value of Immunotherapy-induced Organ Inflammation Assessed on 18FDG PET in Patients With Metastatic Non–small Cell Lung Cancer

2021 ◽  
Author(s):  
Olivier HUMBERT ◽  
Matteo BAUCKNEHT ◽  
Jocelyn GAL ◽  
Marie PAQUET ◽  
David CHARDIN ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Sensitivity And Specificity ◽  
Cell Lung Cancer ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Tumor Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
18Fdg Pet

Abstract PurposeWe evaluated the prognostic value of immunotherapy-induced organ inflammation observed on 18FDG PET in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPI).MethodsData from patients with IIIB/IV NSCLC included in two different prospective trials were analyzed. 18FDG PET/CT exams were performed at baseline (PETBaseline) and repeated after 7-8 weeks (PETInterim1) and 12-16 weeks (PETInterim2) of treatment, using iPERCIST for tumor response evaluation. The occurrence of abnormal organ 18FDG uptake, deemed to be due to ICPI-related organ inflammation, was collected.ResultsExploratory cohort (Nice, France): PETinterim1 and PETinterim2 revealed the occurrence of at least one ICPI-induced organ inflammation in 72.8% of patients, including: midgut/hindgut inflammation (33.7%), gastritis (21.7%), thyroiditis (18.5%), pneumonitis (17.4%), and other organ inflammations (9.8%). iPERCIST tumor response was associated with improved Progression Free Survival (p<0.001). iPERCIST tumor response and immuno-induced gastritis assessed on PET were both associated with improved Overall Survival (OS) (p<0.001 and p=0.032). Combining these two independent variables, we built a model predicting patients 2-year OS with a sensitivity of 80.3% and a specificity of 69.2% (AUC=72.7).Validation cohort (Genova, Italy): Immuno-induced gastritis (19.6% of patients) was associated with improved OS (p=0.04). The model built previously predicted 2-years OS with a sensitivity and specificity of 72.0% and 63.6% (AUC=70.7) and 3-years OS with a sensitivity and specificity of 69.2% and 80.0% (AUC= 78.2).ConclusionImmuno-induced gastritis revealed by early interim 18FDG PET in around 20% of patients with NSCLC treated with ICPI, is a novel and reproducible imaging biomarker of improved OS.

Optimierung der Bestrahlungsplanung beim nicht-kleinzelligen Bronchialkarzinom (NSCLC) mit Hilfe von 18FDG-PET

2002 ◽  
Vol 41 (05) ◽  
pp. 217-220 ◽  
Author(s):  
U. Nestle ◽  
K. Walter ◽  
N. Licht ◽  
D. Ukena ◽  
K. Schnabel ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Fdg Pet ◽  
Small Cell ◽  
Small Cell Lung ◽  
18Fdg Pet

ZusammenfassungZiel: Die FDG-PET-Untersuchung hat in den vergangenen Jahren bei onkologischen Fragestellungen insbesondere beim Staging des Bronchialkarzinoms wachsende Bedeutung erlangt. In der vorliegenden retrospektiven Untersuchung wurde der Einfluss der PET auf die Strahlentherapieplanung bei Patienten mit non-small-cell lung cancer (NSCLC) untersucht. Methoden: Die Untersuchung umfasste 39 Patienten mit einem NSCLC, die zwecks Staging mit PET untersucht worden waren. Sie wurden über (anhand der CT- und Bronchoskopiebefunde geplante) anterior/posteriore Gegenfelder bestrahlt, die den Primärtumor und das Mediastinum einschlossen. Die Ergebnisse der PET-Untersuchung wurden bei der Bestrahlungsplanung zunächst nicht berücksichtigt. Retrospektiv wurden anhand der FDG-Anreicherungen die Bestrahlungsfelder unter Berücksichtigung der Größe und Lokalisation des Primärtumors neu definiert, weiterhin wurde die Ausdehnung des mediastinalen Anteils der Feldkonturen auf PET-Aktivitäten außerhalb des Bestrahlungsfelds überprüft. Ergebnisse: Bei 15 von 39 Patienten unterschieden sich die CT- von den CT/PET-geplanten Bestrahlungsfeldern. In den meisten Fällen (n = 12) war das CT/PET-Feld kleiner als das CT-Feld. Die mediane Größe der Bestrahlungsfelder betrug 179 cm2 und nach Neudefinition durch PET 166 cm2. Bei 20 Patienten mit Tumor-verursachten Belüftungsstörungen (Atelektasen, Dystelektasen) wurde die Änderung des Bestrahlungsfelds signifikant häufiger (p = 0,03) als bei den übrigen Patienten vorgeschlagen. Schlussfolgerung: Unsere Ergebnisse zeigen den Synergismus von topographischer (CT) und metabolischer (FDG-PET) Information, die in der Bestrahlungsplanung des Bronchialkarzinoms insbesondere bei Patienten mit Belüftungsstörungen von Nutzen sein könnte.

Prognostic value of pre-treatment 18F-FDG-PET uptake in small-cell lung cancer

2017 ◽  
Vol 31 (6) ◽  
pp. 462-468 ◽  
Author(s):  
Meryem Aktan ◽  
Mehmet Koc ◽  
Gul Kanyilmaz ◽  
Berrin Benli Yavuz
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Small Cell ◽  
Small Cell Lung ◽  
18F Fdg ◽  
Pre Treatment

Prognostic value of different standard uptake values (SUV) of primary tumor measured with FDG-PET in resectable non-small cell lung cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 7214-7214
Author(s):  
W. K. De Jong ◽  
H. F. Van der Heijden ◽  
J. Pruim ◽  
W. J. Oyen ◽  
H. J. Groen
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Cell Lung Cancer ◽  
Primary Tumor ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Small Cell ◽  
Whole Body ◽  
Small Cell Lung

7214 Background: The SUV is a measure for the preferential uptake of a radiopharmaceutical in a tumor compared with a homogenous distribution in a body. SUV can be based on the maximum value (SUVmax) or on the mean value in a region outlined by isodensity contours, e.g., 70% and 50%. The prognostic value of the different SUVs in non-small cell lung cancer (NSCLC) is not clear. We evaluated the prognostic value of SUVmax, SUV 70% and SUV 50% in patients (pts) with resectable NSCLC. Methods: All consecutive pts who underwent an attenuation corrected whole body FDG-PET scan were selected. All data were reconstructed iteratively. Only pts with stage I through IIIA NSCLC were included. By adjusting the isocontour in the region of interest, the SUVmax, SUV 70% and SUV 50% of the primary tumor were calculated. Cox regression analysis was used to calculate the relation between the different SUVs and survival. Results: Eighty-four pts (67 males, median age 64 years, range 38–86) were included. Histology was squamous cell carcinoma (n = 43), adenocarcinoma (n = 27), large cell carcinoma (n = 13), and 1 patient with bronchoalveolar carcinoma. Nineteen pts had stage IA, 28 stage IB, 4 stage IIA, 19 stage IIB, and 14 stage IIIA. Median (range) SUVmax, SUV 70%, and SUV 50% were 6.9 (1.6–32.5), 5.5 (1.0–23.2), and 4.5 (0.9–21.9), respectively. Analysis of residuals of SUVmax as a continuous variable suggests no cut-off point and no indication of time-dependency. By univariate analysis, all pts with a SUV higher than the median value had a worse survival than pts with a SUV lower than median (Hazard ratio’s for SUVmax, SUV70% and SUV 50% were 2.3 (p = 0.024), 2.5 (p = 0.015), and 2.7 (p = 0.010), respectively). Conclusions: SUVmax, SUV 70% and SUV 50% measured with FDG-PET have a similar prognostic impact. No cut-off point for SUVmax has been observed. No significant financial relationships to disclose.

Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy

Lung Cancer ◽  
2011 ◽  
Vol 71 (1) ◽  
pp. 49-54 ◽  
Author(s):  
Yohei Imamura ◽  
Koichi Azuma ◽  
Seiji Kurata ◽  
Satoshi Hattori ◽  
Tetsuro Sasada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document